Loomis Sayles & CO L P Xenon Pharmaceuticals Inc. Transaction History

Loomis Sayles & CO L P

  • $79.2 Billion
  • Q4 2024

A detailed history of Loomis Sayles & CO L P transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 687,145 shares of XENE stock, worth $24.8 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
687,145
Previous 707,222 2.84%
Holding current value
$24.8 Million
Previous $27.8 Million 3.26%
% of portfolio
0.03%
Previous 0.04%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
SELL
$38.14 - $45.74 $765,736 - $918,321
-20,077 Reduced 2.84%
687,145 $26.9 Million
Q3 2024

Nov 13, 2024
BUY
$36.12 - $43.96 $1.7 Million - $2.06 Million
46,964 Added 7.11%
707,222 $27.8 Million
Q2 2024

Aug 13, 2024
SELL
$36.25 - $43.75 $951,635 - $1.15 Million
-26,252 Reduced 3.82%
660,258 $25.7 Million
Q1 2024

May 14, 2024
SELL
$42.66 - $50.04 $929,348 - $1.09 Million
-21,785 Reduced 3.08%
686,510 $29.6 Million
Q4 2023

Feb 13, 2024
SELL
$28.7 - $46.46 $643,482 - $1.04 Million
-22,421 Reduced 3.07%
708,295 $32.6 Million
Q3 2023

Nov 09, 2023
SELL
$34.16 - $39.73 $779,189 - $906,241
-22,810 Reduced 3.03%
730,716 $25 Million
Q2 2023

Aug 11, 2023
SELL
$34.84 - $43.54 $245,308 - $306,565
-7,041 Reduced 0.93%
753,526 $29 Million
Q1 2023

May 11, 2023
BUY
$33.46 - $40.35 $2.79 Million - $3.37 Million
83,402 Added 12.32%
760,567 $27.2 Million
Q4 2022

Feb 10, 2023
BUY
$33.06 - $39.43 $22.4 Million - $26.7 Million
677,165 New
677,165 $26.7 Million

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.24B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email